Why is VERA down?
Down 1% on Nov 6, and still 16% under its Nov 5 close.
- Its Nov 5 results:
Down 1% on Nov 6, and still 16% under its Nov 5 close.
VERA's Quality Score fell 1 point on Fri, Nov 20, to -6. It closed away from its high of the day (2 chart checks stopped).
Follow VERA's trial news. Pro members can get an alert when Vera Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | A $415M loss |
| Latest filing | 8-K, Nov 5 |
After its last 4 reports it closed -1.4% on average, higher 1 of 4 times.
About 4 quarters
CEO Marshall Fordyce sold 18,500 shares on Sep 15, under a planned sale. 12 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
VERA is #197 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 197 |
Expected to report Thu Feb 25, after the close (in 96 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $1.30 a share, from $1.26.
“The decrease was primarily due to a reduction in contract manufacturing expenses, as manufacturing costs for TRUTAKNA commercial supply, which were previously categorized as research and development expense, have been capitalized as inventory since its accelerated approval on July 7, 2026.”
VERA's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Selling, general and administrative expenses were $61.4 million, compared with $27.5 million during the prior year period, reflecting investment in the commercial launch of TRUTAKNA.”
From its results filing (SEC filing · Nov 5)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | +1.1% | -1.2% | -3.6% |
| Aug 10, 2026 | +1.2% | -4.1% | +0.2% |
| May 7, 2026 | -0.3% | -1.9% | +7.0% |
| Feb 26, 2026 | -1.1% | +1.6% | -4.9% |
RSI 35.9, MACD below signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: VERA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
VERA scores -6 today, which Breakaway calls Poor. It is #197 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 1% on Nov 6, and still 16% under its Nov 5 close. Cash lasts about 4 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
VERA scores -6 today, which Breakaway calls Poor (below zero). That is #197 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind VERA's -6.
Expected to report Thu Feb 25, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. VERA closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.